Key Takeaways
CGM can answer defined clinical questions, especially in diabetes. For healthy adults without symptoms, there is no agreed interpretation system and little evidence that wearing a sensor alone improves health.
- FDA clearance allows certain CGMs to be sold over the counter to adults who do not use insulin. It does not establish a health benefit for healthy users. [1]
- Eighteen specialists showed poor agreement when judging 20 deliberately difficult reports from people without diabetes. [2]
- The expert exercise did not validate the diabetes threshold of 2% of readings above 180 mg/dL for people without diabetes. [2] [3]
- A 25-trial review mainly covered diabetes. Its three non-diabetes trials enrolled people with obesity and combined CGM with other support. [4]
- Diagnosis of diabetes or prediabetes still relies on validated laboratory criteria and clinical context, not one consumer CGM trace. [5] [1]
What is stable
- CGM is established for many people with diabetes, particularly when treatment decisions or hypoglycemia risk depend on glucose patterns. [6]
- Interstitial sensor glucose is not identical to a laboratory plasma-glucose measurement and can diverge during rapid change. [1]
- Normal post-meal rises occur, and a single high sensor value is not a diagnosis. [5] [1]
What remains uncertain
- There is no validated set of CGM thresholds that predicts better outcomes in healthy, asymptomatic adults. [2]
- Short-term dietary changes after feedback have not yet been tied to durable improvements in weight or clinical events for people without diabetes. [4]
- Age, meals, body composition, sensor model and sampling rules contribute to the spread seen in reference cohorts. [2]
Common questions
Can a consumer CGM diagnose prediabetes?
No. A sensor may prompt a clinical discussion, but diagnosis uses validated plasma-glucose or HbA1c criteria, repeat testing when appropriate and the person's clinical context. [5] [1]
Is a brief rise above 140 mg/dL abnormal?
Not by itself. Post-meal glucose varies, and no single consumer-CGM threshold has been validated as a disease marker for healthy adults. [2] [5]
What does FDA clearance of Lingo establish?
It establishes that the device may be marketed for adults who do not use insulin under its stated conditions. The FDA summary says users should not take medical action from the output without professional consultation. [1]
Why did the 18 experts disagree?
The cases were selected to be difficult, and the field lacks accepted interpretation rules for people without diabetes. The exercise demonstrates uncertainty rather than the error rate in routine practice. [2]
Does CGM produce weight loss?
The reviewed trials do not isolate that effect in healthy adults. The pooled weight result was not statistically significant, and the few non-diabetes trials enrolled people with obesity and supplied additional support. [4]
When can CGM have a clear purpose?
It has an established role in diabetes care and may answer a defined question when a clinician can act on the pattern. A healthy user's curiosity is a different use case with a thinner evidence base. [6] [1]
References
- U.S. Food and Drug Administration. (2024). Lingo Glucose System 510(k) decision summary, K233655. https://www.accessdata.fda.gov/cdrh_docs/reviews/K233655.pdf
- Spartano, N. L., Prescott, B., Walker, M. E., et al. (2026). Expert clinical interpretation of continuous glucose monitor reports from individuals without diabetes. Journal of Diabetes Science and Technology, 20(3). https://pubmed.ncbi.nlm.nih.gov/39936548/
- American Diabetes Association Professional Practice Committee. (2026). Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of Care in Diabetes—2026. Diabetes Care, 49(Suppl. 1), S132–S162. https://doi.org/10.2337/dc26-s006
- Richardson, K. M., Jospe, M. R., Bohlen, L. C., et al. (2024). The efficacy of using continuous glucose monitoring as a behaviour change tool in populations with and without diabetes. International Journal of Behavioral Nutrition and Physical Activity, 21, 145. https://doi.org/10.1186/s12966-024-01692-6
- American Diabetes Association Professional Practice Committee. (2026). 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes—2026. Diabetes Care, 49(Suppl. 1), S27–S49. https://diabetesjournals.org/care/article/49/Supplement_1/S27/163926/2-Diagnosis-and-Classification-of-Diabetes
- American Diabetes Association Professional Practice Committee. (2026). Diabetes technology: Standards of Care in Diabetes—2026. Diabetes Care, 49(Suppl. 1), S163–S188. https://doi.org/10.2337/dc26-s007
Related reading
For informational and educational purposes only. This page does not provide individual medical advice, diagnosis, or treatment. Read the full medical disclaimer.